ABVC Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Abvc Biopharma, Inc. had $0.3M of revenue in fiscal 2025, down 41.9% on the year before. Over five years, revenue changed β9.3% a year on average.
Last close Β· Oct 23, 2026
$1.04
0.7%Hi! I read Abvc Biopharma, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β41.9%
No. Sales fell 41.9% last year.
Does it make a profit?
β2,671.8%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Abvc Biopharma, Inc. had $0.3M of revenue in fiscal 2025, down 41.9% on the year before. Over five years, revenue changed β9.3% a year on average. Its operating margin was β2,416.0%, down 1,492.7Β pts: of every 100 in sales, about β2,416 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Abvc Biopharma, Inc. lost $7.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Abvc Biopharma, Inc. owes $0.0M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Abvc Biopharma, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.9M | $0.2M | $0.1M | $0.3M | $0.7M |
| Debt incl. finance leases | $1.6M | $1.9M | $0.9M | $0.8M | $0.8M |
| Debt / equity | 0.2x | 0.6x | 0.6x | 0.7x | 0.1x |
| Interest coverage | β51.5x | β51.4x | β5.2x | β5.7x | β17.2x |
| Current ratio | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Quick ratio | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Total assets | $13.7M | $9.6M | $7.8M | $7.5M | $21.1M |
| Total liabilities | $4.8M | $6.3M | $6.5M | $6.8M | $7.8M |
| Shareholders' equity | $8.8M | $3.1M | $1.6M | $1.2M | $11.1M |
| Net debt (β = net cash) | β$4.3M | $1.7M | $0.8M | $0.5M | $0.0M |
KIRA Β· Its return on capital was β50.8%: every 100 invested in the business earned about β51 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Abvc Biopharma, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | β / 6 | 6 / 9 | 3 / 9 | 4 / 9 | 3 / 9 | 3 / 9 | 6 / 9 | 4 / 8 |
| Accruals ratio | β20.1% | β175.4% | β120.3% | β12.4% | β65.1% | β41.4% | β77.5% | β41.5% | β40.4% | β34.4% |
| Altman Z'' | β | β34.40 | β21.89 | β16.46 | β10.97 | β11.08 | β30.52 | β36.16 | β37.63 | β13.82 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | β | $0.0M | $0.7M | $0.5M | $0.4M | $1.0M | $0.2M | $0.5M | $0.3M |
| Gross profit | $0.0M | β | β$0.2M | $0.7M | $0.5M | $0.4M | $0.7M | β$0.1M | $0.5M | β |
| Research and development | β | $3.2M | $1.0M | $1.0M | $0.5M | $1.0M | $2.7M | $1.1M | $0.2M | $0.1M |
| Operating income | β | β$4.0M | β$2.8M | β$3.5M | β$8.5M | β$11.7M | β$15.1M | β$6.8M | β$4.7M | β$7.2M |
| Interest expense | $0.0M | $0.1M | $0.5M | $0.5M | $0.4M | $0.2M | $0.3M | $1.3M | $0.8M | $0.4M |
| Pretax income | β$0.0M | β$4.1M | β$6.4M | β$4.0M | β$10.8M | β$11.2M | β$15.5M | β$8.0M | β$5.4M | β$8.4M |
| Income tax | β | $0.0M | β$0.4M | β$0.1M | β$0.2M | $0.8M | $0.8M | $0.3M | β$0.1M | $0.0M |
| Net income | β$0.0M | β$4.1M | β$6.1M | β$3.9M | β$10.6M | β$12.8M | β$16.4M | β$7.8M | β$4.9M | β$7.9M |
| Net income to common | β | β | β | β | β$9.8M | β$12.8M | β$16.4M | β | $5.3M | β |
| Diluted EPS | β$0.01 | β$0.02 | β$0.02 | β$0.21 | β$0.50 | β$0.51 | β$5.19 | β$1.80 | β$0.42 | β$0.39 |
| Diluted shares | 0.01B | 0.21B | 0.21B | 0.02B | 0.02B | 0.03B | 0.00B | 0.00B | 0.01B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $0.0M | β$1.6M | β$0.9M | β$3.1M | β$4.6M | β$7.6M | β$7.4M | β$4.2M | β$1.8M | β$3.0M |
| Capital expenditure | β | β | β | β | β | $0.0M | $0.1M | $0.0M | β | β |
| Free cash flow | β | β | β | β | β | β$7.6M | β$7.5M | β$4.2M | β | β |
| Depreciation and amortization | β | β | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | β | $0.1M | $0.0M | $0.0M | $4.1M | $5.3M | $7.0M | $0.2M | $2.8M | $4.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.2M | $0.4M | $0.2M | $0.1M | $4.3M | $5.9M | $0.2M | $0.1M | $0.3M | $0.7M |
| Total debt | β | β | $0.9M | $1.9M | $1.6M | $1.6M | $1.9M | $0.9M | $0.8M | $0.8M |
| Current assets | $0.2M | $2.6M | $0.6M | $0.9M | $6.2M | $7.7M | $3.0M | $1.7M | $2.2M | $2.5M |
| Current liabilities | β | $4.4M | $11.0M | $6.8M | $4.8M | $3.7M | $5.5M | $6.1M | $6.6M | $6.2M |
| Inventory | β | β | $0.0M | β | β | $0.0M | β | β | β | β |
| Property and equipment, net | β | β | $0.5M | $0.5M | $0.5M | $0.5M | $0.6M | $0.6M | $0.5M | $12.8M |
| Total assets | $0.2M | $2.6M | $5.9M | $6.9M | $11.6M | $13.7M | $9.6M | $7.8M | $7.5M | $21.1M |
| Total liabilities | $6.6M | $4.4M | $11.3M | $7.1M | $8.9M | $4.8M | $6.3M | $6.5M | $6.8M | $7.8M |
| Shareholders' equity | β$6.4M | β$1.8M | β$5.7M | β$0.2M | $3.4M | $8.8M | $3.1M | $1.6M | $1.2M | $11.1M |
| Margins | ||||||||||
| Gross margin | 82.4% | β | β2,547.1% | 97.1% | 96.1% | 98.6% | 70.5% | β98.2% | 99.8% | β |
| Operating margin | β | β | β39,780.0% | β492.9% | β1,761.0% | β3,290.1% | β1,558.5% | β4,440.1% | β923.3% | β2,416.0% |
| EBITDA margin | β | β | β39,157.1% | β485.1% | β1,753.4% | β3,286.7% | β1,556.1% | β4,421.4% | β917.0% | β2,407.4% |
| Net margin | β950.0% | β | β86,635.7% | β560.5% | β2,193.3% | β3,608.4% | β1,693.5% | β5,110.3% | β962.1% | β2,671.8% |
| FCF margin | β | β | β | β | β | β2,140.3% | β775.2% | β2,761.2% | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β168.3% | β846.2% | β203.4% | β247.1% | β231.0% | β212.0% | β50.8% |
| Return on capital employed | β | 227.5% | 55.2% | β3,044.7% | β125.8% | β117.0% | β374.5% | β402.2% | β478.9% | β48.0% |
| Return on equity | β | β | β | β | β644.5% | β209.1% | β275.0% | β334.8% | β352.7% | β128.2% |
| Return on assets | β18.2% | β288.7% | β141.3% | β61.1% | β114.3% | β101.5% | β141.1% | β89.7% | β64.0% | β55.3% |
| Return on tangible equity | β | β | β | β | β284.8% | β145.2% | β530.0% | β501.1% | 428.9% | β71.2% |
| Growth | ||||||||||
| Revenue growth | β | β | β | 9,924.3% | β31.2% | β26.3% | 172.6% | β84.3% | 234.4% | β41.9% |
| Share count change | β | 4,152.2% | 0.6% | β91.8% | 12.7% | 27.1% | β87.4% | 36.9% | 169.3% | 72.3% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.5x | 0.2x | 0.6x | 0.6x | 0.7x | 0.1x |
| Interest coverage | β | β53.3x | β6.0x | β7.2x | β21.0x | β51.5x | β51.4x | β5.2x | β5.7x | β17.2x |
| Current ratio | β | 0.6x | 0.1x | 0.1x | 1.3x | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Quick ratio | β | 0.6x | 0.1x | 0.1x | 1.3x | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | β | 4.9% | 12.3% | 13.9% | β | β |
| Stock comp / revenue | β | β | 411.4% | 3.2% | 858.6% | 1,491.5% | 725.6% | 122.0% | 544.3% | 1,399.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | 6.0 | 3.0 | 4.0 | 3.0 | 3.0 | 6.0 | 4.0 |
| Altman Z'' | β | β34.4 | β21.9 | β16.5 | β11.0 | β11.1 | β30.5 | β36.2 | β37.6 | β13.8 |
| Accruals ratio | β20.1% | β175.4% | β120.3% | β12.4% | β65.1% | β41.4% | β77.5% | β41.5% | β40.4% | β34.4% |
Source: SEC EDGAR XBRL filings (CIK 0001173313). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
